Radioimmunotherapy of Non. Hodgkin Lymphoma with
|
|
- Amos Adams
- 6 years ago
- Views:
Transcription
1 Amar U. Kishan, MS Amar IV U. Kishan, MSIV Gillian Lieberman, Gillian MD Lieberman, MD June 2011 Click to edit Master title style Click to edit Master text styles Radioimmunotherapy of Non Second level Hodgkin Lymphoma with Third level 90 Y Ibritumomab Fourth level tiuxetan Fifth level Amar U. Kishan, Harvard Medical School Year IV 1
2 Outline Review of Radioactive Decay Introduction to Radioimmunotherapy 90 Y IT: Brief Literature Review Mechanics of 90 Y IT Therapy Selected Cases 2
3 Review of Radioactive Decay Alpha Decay: Release of an α particle, or helium nucleus. These particles are highly ionizing, and consequently lose energy very quickly, leading to a low penetration depth (these can be shielded by the skin or a piece of paper). Beta Decay: Release of a β particle, either an electron or a positron (along with an antineutrino or neutrino). β particles have higher penetration depths than α particles (shielding can require thin plastic, glass, aluminum, wood). From Wikipedia Commons. Available at: and 3
4 Review of Radioactive Decay Gamma Decay: Release of a γ particle, or photon. As it has no charge or mass, a gamma particle has a high penetration depth (shielding thus requires dense materials like lead or concrete). Composition Alpha Beta Gamma Helium Nucleus Electron or positron Hazard Internal Superficial, Internal Photon External Shielding Paper/Skin Plastic Lead From Wikipedia Commons. Available at: 4
5 Introduction to Radioimmunotherapy Image adapted from Karesh, Stephen. "Radioimmunotherapy of Non Hodgkin's Lymphoma with Radiolabeled Antibodies." April
6 Radioimmunotherapy Principles Utilizes the fact that most cells of a given tumor will express a certain antigen, e.g. CD20 Administering an antibody against this antigen will then activate immune mediated killing upon antibody binding Conjugated a radionuclide to the antibody will allow for localized radiation Advantages of radioimmunotherapy Can reach undetected tumor foci Crossfire effect allows irradiation of poorly perfused or non antigen expressing adjacent cell clusters Normal overlying tissues are not irradiated 6
7 Choosing a Radionuclide α emitters such as 211 At, 212 Bi, and 213 Bi have been investigated Path length (χ 90 ; radius over which 90% of particle energy will be dissipated) is microns, on the order of single cell Very short t 1/2 (~1 hr for Bi isotopes) Area of active research γ emitters Large path length, so most of the radiation will escape the local environment 7
8 β Emitters in Radioimmunotherapy 90 Y 131 I t 1/2 (hr) Decay Type Beta Beta, Gamma Particle Energy (MeV) Particle Path Length (mm) Conjugation Chelation w/ tiuxetan Direct iodination Compound Ibritumomab tiuxetan (Zevalin TM ) Tositumomab (Bexxar ) Image adapted from Karesh, Stephen. "Radioimmunotherapy of Non Hodgkin's Lymphoma with Radiolabeled Antibodies." April Table adapted from Goldsmith SJ. Semin Nucl Med 2010; 40:
9 Brief Aside: Follicular Lymphoma Follicular lymphoma is an indolent NHL, with an incidence of ~18,000 cases/year % of patients achieve a complete remission during first line chemotherapy; unfortunately the median duration of remission is only 2 years. There is also a 5%/year risk of transformation to an aggressive B cell lymphoma. Median overall survival remains only 8 10 years. From Lichtman MA, Shafer MS, Felgar RE, et al. Lichtman s Atlas of Hematology: 9
10 90 Y IT: Brief Literature Review Rituximab (Rituxan ) is a chimeric monoclonal antibody targeting CD20, which is expressed on B cells Approved in 1997 for chemotherapy refractory B cell NHL Part of the standard R CHOP regimen for diffuse large B cell lymphoma (DLBCL) in many centers Ibritumomab tiuxetan (IT) is a murine monoclonal IgG 1 κ antibody also targeting CD20 Tiuxetan is a modified diethylene triamine pentaacetic acid (DTPA) moiety used to chelate the yttrium isotope 10
11 90 Y IT: Brief Literature Review Phase I/II trial in 51 pts with relapsed or refractory low grade, intermediate grade or mantle cell NHL (Witzig et al. J Clin Oncol 1999; 17: 3793:3803) ORR of 67% (CR 26%, PR 41%) Median TTP in responders of months 1 pt (2%) had HACA/HAMA response Phase II trial in 30 pts with relapsed or refractory low grade, follicular, or transformed NHL (Wiseman et al. Blood 2002; 99: ) ORR: 83% (CR 37%, PR 40%) Median TTP in responders was
12 90 Y IT: Brief Literature Review Phase II trial in 57 pts rituximab refractory follicular NHL (Witzig et al. J Clin Oncol 2002; 20: ) ORR of 74% (CR 15%, PR 59%) Median TTP in responders of 8.7 months Phase III randomized trial in 143 pts with relapsed or refractory low grade, follicular, or transformed NHL. 73 pts received 90 Y IT, 70 received rituximab (Witzig et al. J Clin Oncol 2002; 20: ) ORR was 80% vs 56% for 90 Y IT and rituximab, respectively (p=0.002) (CR 30% vs 16% [p=0.04]) Median TTP in responders was 11.2 vs 10.1 months (p=0.173). Durable response of at least 6 months was 67% vs 47% (0.030) 12
13 90 Y IT: Brief Literature Review From Witzig TE et al. J Clin Oncol 2002; 20: (left) and Schering AG. European Pharmacotherapy 2005 (right). 13
14 90 Y IT: Brief Literature Review Phase III randomized trial in patients with stage III or IV follicular lymphoma who received a response to induction. 208 had consolidation with 90 Y IT, 206 did not. (Morschhauser et al. JCO 2008; 26: ) Pts with consolidation had PFS of 36.5 months, vs 13.3 months in control arm (p<0.0001) 77% of patients with advanced follicular lymphoma who a PR with induction therapy converted to CR/CRu with 90 Y IT 90 Y IT is now FDA approved for first line consolidation therapy of low grade or follicular NHL, and also for second line therapy for relapsed or refractory low grade or follicular NHL. 14
15 Mechanics of 90 Y IT Therapy 111 In IT is used initially because it is a gamma emitter; thus, one can track the biodistribution of IT with a gamma camera before carrying out the therapeutic intervention, which occurs on days 7,8, or 9 with the beta emitting 90 Y IT Why is rituximab being administered in this protocol? From Goldsmith SJ. Semin Nucl Med 2010; 40:
16 Mechanics of 90 Y IT Therapy Prior administration of a cold antibody is thought to be necessary in order to soak up sites in the spleen and on circulating normal B cells, such that later administration of the therapeutic antibody will home to tumor foci. For 90 Y IT, the analogous cold antibody is rituximab. From Wahl RL. J Nucl Med 2005; 46: 128S 140S. 16
17 Sample 111 In IT Scan Administered radiotracer dose was approximately 185 MBq (5 mci) of 111 In. Note relative increase in RLQ and mid abdominal lymphatic uptake from hours, reflecting uptake by the lymphoma. From Goldsmith SJ. Semin Nucl Med 2010; 40:
18 Side Effects of 90 Y IT Therapy Grade IV Toxicity Bone Marrow Involvement (n=304 pts) 0 0 5% 5 20% >20% Neutropenia Anemia Thrombocytopenia Myelotoxicity remains the major side effect of 90 Y IT therapy. Patients require a CBC every week for 6 weeks; there is an expected nadir on week 6 7, and full recovery is anticipated 12 weeks after treatment. Contraindications: Bone marrow involvement>25% <1500 PMN/μL, plateletes <100,000/ μ L Myelodysplastic or very hypocellular marrow Pregnancy Altered biodistribution of 111 In IT From Emmanouilides C. J Clin Exp Hematop. 2007; 47:
19 Our First Patient: JD 67 y/o F with following oncologic history: Noticed lump on left neck; bx showed low grade follicular CD20+ NHL. CT scan showed mediastinal and retroperitoneal LAD. Tx d with rituximab, entered remission. Three years later: Noticed lump near ear; pre auricular lymph node dissection showed low grade follicular CD20+ follicular NHL, thought to be a recurrence. CT showed ~10 mm anterior mediastinal lymph node but no other evidence of disease. How about 90 Y IT? 19
20 Pt JD: 111 In IT Scan Note that uptake by the liver is greater than uptake by the lungs or kidneys. Fortunately for the patient, the tumor burden is low enough that focal tumor uptake cannot be appreciated on this scan. From PACS, BIDMC 20
21 Pt JD: Response on Coronal C+ Chest CT From PACS, BIDMC 1 month before 90 Y IT 2 months after 90 Y IT Anterior mediastinal lymphadenopathy (blue box) before (left) and after (right) 90 Y IT. 21
22 Our Next Patient: JD, Jr. 58 y/o F with following oncologic history: Began experiencing n/v, abdominal pain. Colonoscopy showed diffuse nodules in the terminal ileum; bx showed low grade CD20+ follicular NHL. She completed six cycles of R CHOP. PET CT after four cycles showed near complete response, but persistent focal thickening in the terminal ileum was found on MRE. ANOTHER CANDIDATE FOR 90 Y IT 22
23 Pt JD, Jr,: 111 In IT Scan 111 In IT pre scan. Again, focal tumor uptake cannot be appreciated on this scan. From PACS, BIDMC 23
24 Pt JD, Jr.: Lack of Response on Coronal MRI From PACS, BIDMC 1 month before 90 Y IT 2 months after 90 Y IT Terminal ileal wall thickening (blue box) before (left) and after (right) 90 Y IT. Note: These are FIESTA (Fast Imaging Employing Steady state Acquisition) MRI images. 24
25 JD, Jr.: Post 90 Y IT Course Given persistence of ileal thickening, an ileocecectomy was performed. Fortunately, no evidence of lymphoma was found. Over a year later, JD, Jr. is doing well and has no evidence of recurrent disease. Did she even have residual disease prior to 90 Y IT administration? This question cannot be answered. As exemplified by both cases, the 111 In scan will not allow direct visualization of lymphoma in the setting of non bulky disease perhaps the setting in which 90 Y IT therapy is the most helpful. The 111 In scan has limited spatial and contrast resolution and cannot supplant a PET CT. 25
26 Our Last Patient: JD, III 46 y/o M with following oncologic history: Presented with syncope x1 in setting of cough, SOB, night sweats, and ~10 lb weight loss over 8 weeks. Found to have pericardial effusion with tamponade physiology. Tap revealed malignant effusion secondary to primary mediastinal B cell lymphoma (CD20+ NHL). Refractory to 4 months of EPOCH. Given severity of disease, was treated with ICE R and BEAM with goal of asct. 90 Y IT was added to this in further hopes of eradicating the disease. 26
27 Pt JD, III: Evidence of Bulky Disease From PACS, BIDMC Marked subcarinal lymph node enlargement on presentation (blue box) is easily seen on this axial C+ CT image. 27
28 Selected Case: Pt JD, III Left esophageal and anterior epicardial (left) and left anterior diaphragmatic (right) lymphadenopathy is easily appreciated on these axial C+ CT images. From PACS, BIDMC 28
29 Pt JD, III: 111 In IT Scan Possible focal tumor uptake over right shoulder, but, again, difficult to draw conclusions. From PACS, BIDMC 29
30 Pt JD, III: Post 90 Y IT Course Following 90 Y IT infusion, interval PET imaging did show improvement in lymphadenopathy, and pt underwent an asct. However, serial CT scanning three months later was not promising 30
31 Pt JD, III: Relapse on Axial C+ CT Marked resolution of subcarinal lymphadenopathy (left, blue box) but numerous hypoattenuating foci (right, blue boxes) suggestive of widespread disease. Pt expired within 1 month. 31 From PACS, BIDMC
32 Our Three Patients: An Update Pt JD: 67 y/o F with relapsed follicular lymphoma had an excellent response to 90 Y IT therapy. She remains in remission four months later. Pt JD, Jr: 58 y/o F with ileal follicular lymphoma ultimately underwent an ileocectomy as mentioned. She is disease free two years later. Pt JD, III: 46 y/o M with primary mediastinal B cell lymphoma, ultimately underwent an asct. He expired within 1 month of detection of hepatic and splenic involvement. 32
33 Summary 90 Y ibritumomab tiuextan (Zevalin TM ) is an effective agent that is FDA approved for first line consolidation therapy of low grade or follicular NHL, and also as a second line agent for relapsed or refractory low grade or follicular NHL. It binds to the CD20 receptor found on B cells. The 90 Y is a beta emitter; therapeutic effect is derived from the fact that the path length of released beta particles is ~5.3 mm, leading to death of numerous adjacent tumor cells regardless of their CD20 status. As a pure beta emitter, 90 Y IT poses limited if any external threat. Only minor precautions regarding body fluid handling need to be observed. The major adverse effect is myelotoxicity. 33
34 Acknowledgements J. Anthony Parker, MD, PhD Yiming Gao, MD Mrs. Emily Hanson 34
35 References Ansell SM, Schilder RJ, Pieslor PC, et al. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non Hodgkin's lymphoma: a review of the literature. Clin Lymphoma. 2004; 5: DeNardo GL, O'Donnell RT, Rose LM, et al. Milestones in the development of Lym 1 therapy. Hybridoma 1999; 18:1 11. DeNardo SJ, Williams LE, Leigh BR, et al. Choosing an optimal radioimmunotherapy dose for clinical response. Cancer. 2002; 94: Emmanouilides C. Radioimmunotherapy for non hodgkin lymphoma : historical perspective and current status. J Clin Exp Hematop. 2007; 47: Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010; 40: Kaminski MS, Tuck M, Estes J, et al. 131I tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005; 352: Karesh, Stephen. "Radioimmunotherapy of Non Hodgkin's Lymphoma with Radiolabeled Antibodies." April nhl/index.html. Accessed June 10, Lichtman MA, Shafer JA, Felgar RE, et al. C. Mature B Cell Lymphomas and Myelomas. In: Lichtman MA, Shafer JA, Felgar RE, Wang N: Lichtman's Atlas of Hematology: Mattes MJ. Radionuclide antibody conjugates for single cell cytotoxicity. Cancer. 2002; 94: Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium 90 ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008; 26: Schering AG. Zevalin an Emerging Treatment Option in Non Hodgkin s Lymphoma. Business Briefing: European Pharmacotherapy. 2005; 2:1 7. Wahl RL. Tositumomab and 131 I therapy in non Hodgkin's lymphoma. J Nucl Med. 2002; 46:128S 140S. Wikipedia Commons. Available at: Accessed June 10, Wikipedia Commons. Available at: Accessed June 10, Wikipedia Commons. Available at: Accessed June 10, Wiseman GA, White CA, Witzig TE. Radioimmunotherapy of relapsed non Hodgkin's lymphoma with zevalin, a 90Y labeled anti CD20 monoclonal antibody. Clin Cancer Res. 1999; 5:3281s 3286s. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B cell non Hodgkin's lymphoma. J Clin Oncol. 1999; 17: Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium 90 labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low grade, follicular, or transformed B cell non Hodgkin's lymphoma. J Clin Oncol. 2002; 20: Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab refractory follicular non Hodgkin's lymphoma. J Clin Oncol. 2002; 20: Witzig TE, Molina A, Gordon LI, et al. Long term responses in patients with recurring or refractory B cell non Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer May 1;109(9):
Digital Washington University School of Medicine. Russell Schilder Fox Chase Comprehensive Cancer Center. Arturo Molina Biogen Idec
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2004 Follow-up results of a phase II study of ibritumomab tiuetan radioimmunotherapy in patients with relapsed or
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationScottish Medicines Consortium
Scottish Medicines Consortium ibritumomab tiuxetan (Zevalin ) No. (171/05) Schering Health Care Ltd 8 April 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationThis tutorial gives an overview of Radioimmunotherapy in Non-Hodgkin s Lymphoma. After completing this tutorial, attendees will be able to:
This tutorial gives an overview of Radioimmunotherapy in Non-Hodgkin s Lymphoma. After completing this tutorial, attendees will be able to: Name the radiopharmaceutical approved by the FDA for performance
More informationIndium-111 Zevalin Imaging
Indium-111 Zevalin Imaging Background: Most B lymphocytes (beyond the stem cell stage) contain a surface antigen called CD20. It is possible to kill these lymphocytes by injecting an antibody to CD20.
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationRADIOIMMUNOCONJUGATES
RADIOIMMUNOCONJUGATES TOSITUMOMAB (BEXXAR ) I. MECHANISM OF ACTION Tositumomab and Iodine I 131 tositumomab is an antineoplastic radioimmunotherapeutic monoclonal antibody-based regimen composed of the
More informationIbritumomab Tiuxetan in Lymphoma: A Clinical Practice Guideline
Evidence-based Series #6-17: Section 1 Ibritumomab Tiuxetan in Lymphoma: A Clinical Practice Guideline M. Cheung, A.E. Haynes, A. Stevens, R.M. Meyer, K. Imrie, and the members of the Hematology Disease
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationZEVALIN (ibritumomab tiuxetan) Information for Authorized Users and Administration Facilities
0133-049104 ZEVALIN (ibritumomab tiuxetan) Information for Authorized Users and Administration Facilities Please see slides 3-7 for BOXED WARNINGS and Important Safety Information. Please see full Prescribing
More informationThe radiolabeled monoclonal antibodies 90 Y-ibritumomab
Journal of Nuclear Medicine, published on October 17, 2007 as doi:10.2967/jnumed.107.043489 Comparison of Y-Ibritumomab Tiuxetan and I-Tositumomab in Clinical Practice Heather A. Jacene*, Ross Filice*,
More informationRadio-isotopes in Clinical Medicine
Radio-isotopes in Clinical Medicine Radiactive isotopes, whether naturally occurring or artificially produced, have a number of different uses in clinical medicine. These include: (1) Diagnostic and research
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationBetalutin : a modern approach to treating NHL patients. Arne Kolstad Oslo University Hospital Norway
Betalutin : a modern approach to treating NHL patients Arne Kolstad Oslo University Hospital Norway 1 Speaker credentials Senior Consultant of Medical Oncology and Radiotherapy, Oslo University Hospital,
More informationThe chimeric anti-cd20 antibody rituximab is an integral component
Radioimmunotherapy with Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas Flavio Forrer 1,2, Catharina Oechslin-Oberholzer
More informationbiij Radioimmunotherapy: a brief overview DCE Ng, MBBS, MRCP, FAMS Biomedical Imaging and Intervention Journal REVIEW ARTICLE
Available online at http://www.biij.org/2006/3/e23 doi: 10.2349/biij.2.3.e23 biij Biomedical Imaging and Intervention Journal REVIEW ARTICLE Radioimmunotherapy: a brief overview DCE Ng, MBBS, MRCP, FAMS
More informationTositumomab and iodine I 131 tositumomab (Bexxar ) Corixa Corporation; marketed by GlaxoSmithKline 1
Generic (Trade Name): Manufacturer: Tositumomab and iodine I 131 tositumomab (Bexxar ) Corixa Corporation; marketed by GlaxoSmithKline 1 NO. 64 OCTOBER 2005 Indication: Current Regulatory Status: In the
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationLymphoma is a cancer that develops in the white blood cells (lymphocytes) of the lymphatic system, which is part of the body's immune system.
Scan for mobile link. Lymphoma Lymphoma is a cancer that develops in the white blood cells of the lymphatic system. Symptoms may include enlarged lymph nodes, unexplained weight loss, fatigue, night sweats
More informationRadioimmunotherapy of non-hodgkin lymphomas
Review article Radioimmunotherapy of non-hodgkin lymphomas Bruce D. Cheson Enthusiasm for the use of monoclonal antibodies, such as rituximab, has markedly changed the approach to patients with non-hodgkin
More informationAntibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma
Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma Steven I. Park, MD, 1* and Kristy L. Richards, PhD, MD 1 ABSTRACT Antibody-based immunotherapeutic agents have emerged as important
More informationCLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE
FOR IMMEDIATE RELEASE CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE Results of Studies of BEXXAR TM Therapy Show Promise
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationRadioimmunotherapy for lymphoma analysis of clinical trials and treatment algorithms
Review Nuclear Medicine Review 2007 Vol. 10, No. 2, pp. 110 115 Copyright 2007 Via Medica ISSN 1506 9680 Radioimmunotherapy for lymphoma analysis of clinical trials and treatment algorithms Wojciech Jurczak
More informationClinical Trials? John Buscombe
Clinical Trials? John Buscombe Introduc7on Look at the role of clinical trials in radionuclide therapy Understand some of the terms used in clinical trials Look at two recent examples Commercial trial
More informationNon-Hodgkin lymphomas (NHLs) constitute a heterogeneous. Original Articles
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS Volume 28, Number 5, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/cbr.2012.1387 Original Articles Phase I Study of a Modified Regimen of 90 Yttrium Ibritumomab
More informationNew Horizons in radionuclide therapy. John Buscombe Royal Free Hospital
New Horizons in radionuclide therapy John Buscombe Royal Free Hospital Date for you diary Interested in Radionuclide imaging and therapy using antibodies and peptides IRIST 2008 Krakow Poland 18-21 June
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationTechnical Considerations in Zevalin Radioimmunotherapy Kathy Thomas, MHA, CNMT City of Hope National Medical Center
Technical Considerations in Zevalin Radioimmunotherapy Kathy Thomas, MHA, CNMT City of Hope National Medical Center Technical Considerations in Zevalin Radioimmunotherapy Objectives: Explain the technical
More informationRadioimmunotherapy for B-Cell Non-Hodgkin Lymphomas
Radioimmunotherapy is an effective but underutilized treatment option for patients with B-cell non-hodgkin lymphoma in both the front-line and the relapsed/refractory setting. George Van Hook. Flyfishing.
More informationTreatment with anti-cd20 monoclonal antibodies is the
Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of Nuclear Medicine Physicians and Radiation Oncologists Niklaus G. Schaefer 1, Peng Huang 2, Julia W. Buchanan 1, and Richard L. Wahl 1 1 Division
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIbritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals) Y-Ibritumomab Tiuxetan in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin s Lymphoma*
CONTINUING EDUCATION Y-Ibritumomab Tiuxetan in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin s Lymphoma* Darlene M. Fink-Bennett, MD 1 ; and Kathy Thomas, MHA, CNMT 2 1 Department of Nuclear
More information*Please see amendment for Pennsylvania Medicaid at the
1 of 32 Number: 0659 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. I. Ibritumomab tiuxetan (Zevalin) Aetna considers radioimmunotherapy with ibritumomab tiuxetan (Zevalin)
More informationTiuxetan ( 90 Y-IT) as a consolidation
Aim of the study: To evaluate the efficacy and safety of Yttrium-90 Ibritumomab Tiuxetan ( 90 Y-IT) as a consolidation therapy in the management of DLBCL. Material and methods: Patients with primary refractory
More informationtry George Sgouros, Ph.D. Russell H. Morgan Dept of Radiology & Radiological Science Baltimore MD
Bexxar Dosimet try George Sgouros, Ph.D. Russell H. Morgan Dept of Radiology & Radiological Science Johns Hopkins University, School of Medicine Baltimore MD Clinical i l Experi ience with anti- CD-20
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationVolume Reduction versus Radiation Dose for Tumors in Previously Untreated Lymphoma Patients Who Received Iodine-131 Tositumomab Therapy
1258 Eighth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer Supplement to Cancer Volume Reduction versus Radiation Dose for Tumors in Previously Untreated Lymphoma Patients Who Received
More informationOncologist. The. Harnessing the Energy: Development of Radioimmunotherapy for Patients with Non-Hodgkin s Lymphoma
The Oncologist Harnessing the Energy: Development of Radioimmunotherapy for Patients with Non-Hodgkin s Lymphoma STEPHANIE A. GREGORY, a KARIN HOHLOCH, b CHRISTIAN GISSELBRECHT, c KENSEI TOBINAI, d MARTIN
More informationJULIE M. VOSE. 3. Identify future directions for radioimmunotherapy in cancer medicine.
The Oncologist Lymphoma Bexxar : Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin s Lymphoma JULIE M. VOSE Department of Internal Medicine, University of Nebraska
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationTHE USE OF IBRITUMOMAB AS CONSOLIDATION THERAPY AFTER REMISSION INDUCTION IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
THE USE OF IBRITUMOMAB AS CONSOLIDATION THERAPY AFTER REMISSION INDUCTION IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA Wolfson Unit Claremont Place Newcastle upon Tyne NE2 4HH May 2009 n THE USE OF IBRITUMOMAB
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationRadionuclides in Medical Imaging. Danielle Wilson
Radionuclides in Medical Imaging Danielle Wilson Outline Definitions History and development Radionuclide applications & techniques in imaging Conclusion Definition #1 : Radionuclide An unstable nucleus
More informationBendamustine for relapsed follicular lymphoma refractory to rituximab
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for relapsed follicular lymphoma refractory to rituximab Bendamustine for relapsed follicular lymphoma refractory to rituximab Contents Summary 1
More informationBetalutin for the treatment of recurrent indolent NHL: new insights. Dr. Arne Kolstad 22 November 2017
Betalutin for the treatment of recurrent indolent NHL: new insights Dr. Arne Kolstad 22 November 2017 Betalutin, a new anti-cd37 antibody radionuclide conjugate (ARC) lutetium-177: Beta-particle emitting
More informationRadioimmunotherapy of Non-Hodgkin s Lymphoma: From the Magic Bullets to Radioactive Magic Bullets
YALE JOuRNAL OF BIOLOGY AND MEDICINE 84 (2011), pp.391-407. Copyright 2011. FOCuS: IMMuNOLOGY AND IMMuNOTHERAPEuTICS Radioimmunotherapy of Non-Hodgkin s Lymphoma: From the Magic Bullets to Radioactive
More informationClinical Study Dynamic Metabolic Changes during the First 3 Months after
e Scientific World Journal, Article ID 368947, 6 pages http://dx.doi.org/10.1155/2014/368947 Clinical Study Dynamic Metabolic Changes during the First 3 Months after 90 Y-Ibritumomab Tiuxetan Radioimmunotherapy
More informationPhysical Bases : Which Isotopes?
Physical Bases : Which Isotopes? S. Gnesin Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland 1/53 Theranostic Bruxelles, 2 Octobrer 2017 Theranostic : use of diagnostic
More informationOption D: Medicinal Chemistry
Option D: Medicinal Chemistry Basics - unstable radioactive nuclei emit radiation in the form of smaller particles alpha, beta, positron, proton, neutron, & gamma are all used in nuclear medicine unstable
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationLugano classification: Role of PET-CT in lymphoma follow-up
CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic
More informationDr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA???
Dr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA??? History of Radiotherapy 1895 Rontgen describes X-rays 1896 Becquerel radioactivity 1905 Radiation is used to treat tumours
More informationYttrium ibritumomab tiuxetan in the treatment of non-hodgkin s lymphoma: current status and future prospects
REVIEW Yttrium ibritumomab tiuxetan in the treatment of non-hodgkin s lymphoma: current status and future prospects Samuel A Jacobs University of Pittsburgh School of Medicine, 5150 Centre Avenue, Pittsburgh,
More informationThe role of radiolabeled antibodies in the treatment of non-hodgkin s lymphoma: the coming of age of radioimmunotherapy
Critical Reviews in Oncology/Hematology 39 (2001) 195 201 www.elsevier.com/locate/critrevonc The role of radiolabeled antibodies in the treatment of non-hodgkin s lymphoma: the coming of age of radioimmunotherapy
More informationRadiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2
Radiation and Hodgkin s Disease: A Changing Field Sravana Chennupati Radiation Oncology PGY-2 History of Present Illness 19 yo previously healthy male college student began having pain in his R shoulder
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More information1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationCURRENT STATUS AND POTENTIAL OF ALPHA-EMITTING RADIOPHARMACEUTICALS
CURRENT STATUS AND POTENTIAL OF ALPHA-EMITTING RADIOPHARMACEUTICALS Chaitanya Divgi, MD crdivgi@gmail.com NO DISCLOSURES Objectives Aware of the types of radionuclides with therapeutic potential. Familiar
More informationDownloaded from by guest on 18 November 2018
Radiation Protection Dosimetry Vol. 105, No. 1 4, pp. 581 586 (2003) Published by Nuclear Technology Publishing 2003 Nuclear Technology Publishing ASSESSMENTS FOR HIGH DOSE RADIONUCLIDE THERAPY TREATMENT
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationBetalutin (177Lu-Lilotomab)
Betalutin (177Lu-Lilotomab) Arne Kolstad Oslo University Hospital Norway May 10, 2016 Disclosures of: Arne Kolstad Company name Research support Employee Consultant Stockholder Speakers bureau Nordic Nanovector
More informationPatient Case Studies & Panel Discussion
Patient Case Studies & Panel Discussion Panelists: Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center; Ranjana H. Advani, MD, Stanford Cancer Institute; Andrew D. Zelenetz, MD, PhD, Memorial
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationThe Role of PET / CT in Lung Cancer Staging
July 2004 The Role of PET / CT in Lung Cancer Staging Vlad Vinarsky, Harvard Medical School Year IV Patient AM HPI: 81 yo F p/w hemoptysis x 1 month LLL lesion on CXR, not responsive to Abx 35 pack-year
More informationChapter 5. M.J. Wondergem 1, J.M. Zijlstra 1, M. de Rooij 1, O.J. Visser 1, P.C. Huijgens 1, S. Zweegman 1
Chapter 5 Improving survival in patients with transformed B-cell non Hodgkin lymphoma: consolidation with 90 Yttrium ibritumomab tiuxetan-beam and autologous stem cell transplantation M.J. Wondergem 1,
More informationNuclear Medicine and PET. D. J. McMahon rev cewood
Nuclear Medicine and PET D. J. McMahon 150504 rev cewood 2018-02-15 Key Points Nuclear Medicine and PET: Imaging: Understand how Nuc Med & PET differ from Radiography & CT by the source of radiation. Be
More informationPeptide Receptor Radionuclide Therapy (PRRT) of NET
Peptide Receptor Radionuclide Therapy (PRRT) of NET Dr. Tuba Kendi Associate Prof of Radiology, Mayo Clinic, Rochester, MN 2014 MFMER slide-1 Relevant Financial Relationship(s) None Off Label Usage None
More informationA Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Iodine-131 Tositumomab in Lymphoma
Evidence-based Series 6-19 EDUCATION AND INFORMATION 2013 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Iodine-131 Tositumomab in Lymphoma The Hematology
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAddress correspondence to: Brad S. Kahl, MD 1111 Highland Avenue, 4059 WIMR Madison, WI
Yttrium 90-Ibritumomab Tiuxetan Plus Rituximab Maintenance as Initial Therapy for Patients With High-Tumor-Burden Follicular Lymphoma: A Wisconsin Oncology Network Study Saurabh Rajguru, MD, Thorhildur
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationRadioimmunotherapy in follicular lymphomas, a retrospective analysis of the Polish Lymphoma Research Group s (PLRG) experience
Nuclear Medicine Review 2007 Vol. 10, No. 2, pp. 91 97 Copyright 2007 Via Medica ISSN 1506 9680 Radioimmunotherapy in follicular lymphomas, a retrospective analysis of the Polish Lymphoma Research Group
More informationMonoclonal Antibody Therapy in Lymphoid Malignancies. The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee, USA
The Oncologist Promising New Drugs and Combinations Monoclonal Antibody Therapy in Lymphoid Malignancies JOHN D. HAINSWORTH The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee,
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationHodgkin's Lymphoma. Symptoms. Types
Hodgkin's lymphoma (Hodgkin's disease) usually develops in the lymphatic system, a part of the body's immune system. This system carries disease-fighting white blood cells throughout the body. Lymph tissue
More informationRadiopharmacy. Prof. Dr. Çetin ÖNSEL. CTF Nükleer Tıp Anabilim Dalı
Prof. Dr. Çetin ÖNSEL CTF Nükleer Tıp Anabilim Dalı What is Nuclear Medicine? Nuclear Medicine is the branch of medicine concerned with the use of radionuclides in the study and the diagnosis of diseases.
More informationAuthor Manuscript Faculty of Biology and Medicine Publication
Serveur Académique Lausannois SERVAL serval.unil.ch Author Manuscript Faculty of Biology and Medicine Publication This paper has been peer-reviewed but dos not include the final publisher proof-corrections
More informationNon Transplant-Related Treatment Options in Follicular Lymphoma
Biology of Blood and Marrow Transplantation 12:53-58 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0111$32.00/0 doi:10.1016/j.bbmt.2005.10.003 Non Transplant-Related
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers Recent advances in radiation therapy, such as intensity modulated radiation therapy (IMRT), have
More informationBetalutin, a novel CD37-targeted radioimmunotherapy for NHL. Arne Kolstad Oslo University Hospital 2 October 2018
Betalutin, a novel CD37-targeted radioimmunotherapy for NHL Arne Kolstad Oslo University Hospital 2 October 2018 Disclosures of: Arne Kolstad Company name Research support Employee Consultant Stockholder
More informationASH POSTER: LYMRIT UPDATE
ASH POSTER: LYMRIT 37-01 UPDATE DECEMBER 2018 EDUARDO BRAVO, CEO LISA ROJKJAER, MD, CMO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: ir@nordicnanovector.com
More informationRadioimmunotherapy for B-cell lymphoma: Y 90 ibritumomab tiuxetan and I 131 tositumomab
(2007) 26, 3614 3628 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 REVIEW : Y 90 ibritumomab tiuxetan and I 131 tositumomab www.nature.com/onc Department of Medical Oncology, St
More informationNuclear Oncology Applications
Nuclear Oncology Applications Michael G. Stabin Vanderbilt University Nashville, TN XX Congresso Brasileiro de Física Médica e Simpósio Internacional de Proteção Radiológica em Medicina 12 a 15/Ago/2015
More informationCAR-T CELLS: NEW HOPE FOR CANCER PATIENTS
CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS Natasha Kekre, MD, MPH, FRCPC Hematologist, Blood and Marrow Transplant Program, TOH Associate Scientist, Ottawa Hospital Research Institute Assistant Professor
More information